Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update presentation at the virtual conference on Wednesday, February 12, 2025, at 2:40 p.m. ET. The event, scheduled for February 11-12, 2025, will be held entirely virtually, with a webcast link available for interested participants.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata focalizzata sullo sviluppo di terapie per malattie del sistema nervoso centrale (CNS), infiammatorie e cardiometaboliche, ha annunciato la sua partecipazione alla prossima 35ª Conferenza Annuale sulla Salute e le Scienze della Vita di Oppenheimer.
Il fondatore, presidente e CEO dell'azienda, Laxminarayan Bhat, Ph.D., presenterà un aggiornamento aziendale durante la conferenza virtuale mercoledì 12 febbraio 2025 alle 14:40 ET. L'evento, previsto per l'11 e il 12 febbraio 2025, si svolgerà interamente in modalità virtuale, con un link per il webcast disponibile per i partecipanti interessati.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada centrada en desarrollar terapias para enfermedades del sistema nervioso central (CNS), inflamatorias y cardiometabólicas, ha anunciado su participación en la próxima 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer.
El fundador, presidente y CEO de la empresa, Laxminarayan Bhat, Ph.D., hará una presentación de actualización corporativa en la conferencia virtual el miércoles 12 de febrero de 2025 a las 2:40 p.m. ET. El evento, programado para el 11 y 12 de febrero de 2025, se llevará a cabo completamente en línea, con un enlace de transmisión disponible para los participantes interesados.
레비바 제약 홀딩스 (NASDAQ: RVPH)은 중추 신경계(CNS), 염증 및 심대사 질환에 대한 치료제를 개발하는 데 집중하는 후반기 제약 회사로, 다가오는 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여할 것이라고 발표했습니다.
회사의 창립자이자 회장 겸 CEO인 Laxminarayan Bhat, Ph.D.는 2025년 2월 12일 수요일 오후 2:40 ET에 열리는 가상 컨퍼런스에서 회사 업데이트 발표를 진행할 것입니다. 2025년 2월 11일과 12일로 예정된 이번 행사는 전적으로 온라인으로 진행되며, 관심 있는 참가자를 위한 웹캐스트 링크가 제공될 예정입니다.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), une société pharmaceutique en phase avancée axée sur le développement de thérapies pour les maladies du système nerveux central (CNS), inflammatoires et cardiométaboliques, a annoncé sa participation à la prochaine 35e Conférence Annuelle sur les Sciences de la Vie et de la Santé d'Oppenheimer.
Le fondateur, président et PDG de l'entreprise, Laxminarayan Bhat, Ph.D., fera une présentation de mise à jour de l'entreprise lors de la conférence virtuelle le mercredi 12 février 2025 à 14h40 ET. L'événement, prévu les 11 et 12 février 2025, se déroulera entièrement en ligne, avec un lien de webdiffusion disponible pour les participants intéressés.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), ein fortgeschrittenes Pharmaunternehmen, das sich auf die Entwicklung von Therapien für erkrankungen des zentralen Nervensystems (CNS), entzündliche und kardiometabolische Erkrankungen konzentriert, hat seine Teilnahme an der kommenden 35. jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Oppenheimer angekündigt.
Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird am Mittwoch, den 12. Februar 2025, um 14:40 Uhr ET eine Unternehmenspräsentation während der virtuellen Konferenz halten. Die Veranstaltung, die für den 11. und 12. Februar 2025 geplant ist, wird vollständig virtuell stattfinden, wobei ein Webcast-Link für interessierte Teilnehmer verfügbar sein wird.
- None.
- None.
CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually February 11-12, 2025.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Format: Corporate update
Date: Wednesday, February 12, 2025
Time: 2:40 p.m. ET
Location: Virtual
Webcast Link: Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) presenting at the Oppenheimer Healthcare Conference 2025?
What therapeutic areas does RVPH focus on according to their latest conference presentation?
Is the Oppenheimer Healthcare Conference 2025 where RVPH is presenting in-person or virtual?
Who will represent RVPH at the Oppenheimer Healthcare Conference 2025?
